• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    美

    美国癌症协会

    American Cancer Society
    EST. 1913
    2,054论文总数
    46.2万引用总数

    论文量&引用量时间轴

    机构学者

    论文(2054)

    年份
    起
    –
    止
    排序
    1Cancer Statistics, 2026.
    Rebecca L Siegel, Tyler B Kratzer,Nikita Sandeep Wagle,Hyuna Sung,Ahmedin Jemal

    Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using data collected by central cancer registries (incidence, through 2022) and the National Center for Health Statistics (mortality, through 2023). In 2026, approximately 2,114,850 new cancer cases and 626,140 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2023, averting 4.8 million deaths since 1991, largely because of smoking reductions, earlier detection, and improved treatment. These interventions are also evident in rising 5-year relative survival, which reached a milestone 70% for diagnoses during 2015-2021 overall, 69% for regional-stage disease, and 35% for distant-stage (metastatic) disease, up from 63%, 54%, and 17%, respectively, in the mid-1990s. People with high-mortality cancers and advanced diagnoses had the largest gains, including increases from 32% to 62% for myeloma, 7% to 22% for liver cancer, 16% to 35% for metastatic melanoma, 8% to 18% for metastatic rectal cancer, 20% to 37% for regional lung cancer, and 2% to 10% for metastatic lung cancer. Nevertheless, lung cancer will cause more deaths in 2026 than second-ranking colorectal cancer and third-ranking pancreatic cancer combined. In summary, decades of scientific investment have translated to longer lives for people with even the most fatal cancers. However, continued progress is threatened by proposed federal cuts to cancer research and health insurance, which provides access to life-saving cancer treatment.

    2026CA a cancer journal for clinicians(2026)引用:235
    引用
    AI阅读
    加入学术空间
    2Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 34 Cancers in 186 Countries.
    Hyuna Sung,Adalberto M Filho,Mathieu Laversanne,Jacques Ferlay,Rebecca L Siegel,Isabelle Soerjomataram,Ahmedin Jemal,Freddie Bray

    This article provides updated global cancer statistics for the year 2024 based on the GLOBOCAN estimates of the International Agency for Research on Cancer. The authors describe national cancer incidence and mortality by world region and the Human Development Index and predict the burden in 2050 based on demographic trends. In 2024, an estimated 20.6 million new cancer cases (19.5 million excluding nonmelanoma skin cancer) and 9.8 million deaths (9.7 million excluding nonmelanoma skin cancer) occurred worldwide, equivalent to one in five people developing cancer during their lifetime and one in nine men and one in 13 women dying from the disease. Lung cancer is the most frequently diagnosed cancer, responsible for almost 2.6 million new cases (12.8%), followed by female breast (11.8%), colorectal (9.9%), prostate (7.5%), and stomach (4.7%) cancer. Lung cancer is also the leading cause of cancer death, with an estimated 1.9 million deaths (19.1%), followed by colorectal (9.4%), liver (7.5%), female breast (7.1%), and stomach (6.6%) cancer. Incidence rates vary four- to five-fold across regions, with the highest rates found in Australia/New Zealand (men, 477 per 100,000; women, 396 per 100,000), whereas mortality rates differ two-fold, with elevated rates in Eastern Europe for men (158 per 100,000) and Melanesia for women (108 per 100,000). The incidence burden is predicted to reach 34.4 million by 2050, up 67% from 2024, with the largest proportional increases in lower Human Development Index countries. Although global variation in cancer profiles demands a nuanced approach to cancer control at national and regional levels, primary prevention must be at the forefront, including intensified efforts to reduce tobacco use, prevent infections, lower alcohol consumption and excess body weight, and increase physical activity.

    2026CA a cancer journal for clinicians(2026)引用:45
    引用
    AI阅读
    加入学术空间
    3Colorectal Cancer Statistics, 2026
    Rebecca L Siegel, Nikita Sandeep Wagle,Jessica Star, Tyler B Kratzer, Robert A Smith,Ahmedin Jemal

    Colorectal cancer (CRC) is the second most common cancer-related death in the United States and ranks first in adults younger than 50 years. Every 3 years, the American Cancer Society reports on CRC occurrence based on incidence from population-based cancer registries and mortality from the National Center for Health Statistics. Overall, CRC incidence declined by 0.9% annually during 2013-2022 driven by decreases of 2.5% annually in adults aged 65 years and older. In sharp contrast, incidence rates increased by 3% annually in adults aged 20-49 years and by 0.4% annually in adults aged 50-64 years dominated by tumors in the distal colon and rectum. Consequently, overall rectal cancer incidence increased by 1% annually from 2018 to 2022 after decades of decline and now accounts for 32% of all CRC, up from 27% in the mid-2000s. Increasing CRC incidence in adults aged 50-64 years was confined to regional and distant-stage diagnosis (1.1%-1.3% annually during 2013-2022), likely contributing to an upturn in mortality in this age group of 1% annually since 2019 that was steepest (2.3% annually) in White individuals. Mortality has increased in adults younger than 50 years by 1% annually since 2004, whereas rates have decreased in adults 65 years and older by 2.3% annually since 2012. Despite steady progress for older adults, both CRC incidence and mortality are increasing in adults younger than 65 years who are in the prime of life, underscoring an urgent need for etiologic research to discover the cause of the rising trend. Meanwhile, morbidity and mortality could be mitigated with earlier diagnosis, through screening and educating clinicians and the general public about CRC symptoms, and greater attention to the unique needs of younger patients, including discussion about the preservation of fertility and sexual health.

    2026CA a cancer journal for clinicians(2026)引用:16
    引用
    AI阅读
    加入学术空间
    4American Cancer Society's Report on the Status of Cancer Disparities in the United States, 2025.
    Farhad Islami, Gladys Arias, Dongjun Lee,Daniel Wiese, Jordan Baeker Bispo, K Robin Yabroff,Rebecca L Siegel,Priti Bandi,Nigar Nargis,Alpa V Patel, Paul P Thienprayoon, Arif H Kamal,

    Since 2021, the American Cancer Society has published its biennial report on the status of cancer disparities in the United States. In this 2025 report, the authors provide updated data on disparities in cancer occurrence and outcomes by sex, race, ethnicity, socioeconomic status (SES [educational attainment as a proxy]), and geographic location (including urbanicity of county of residence and congressional district), along with contributors to these disparities, including major cancer risk factors, screening, and select social determinants of health (SDOH) and health‐related social needs. The authors found substantial disparities across the cancer continuum, including risk factors, incidence, stage at diagnosis, receipt of care, survival, and mortality for many cancers and in evaluated SDOH by race and ethnicity, educational attainment, and geographic location. During 2019 through 2023, Black and American Indian/Alaska Native populations had the highest cancer mortality rates, both overall and for the leading causes of cancer death. Cancer mortality rates were also consistently higher among adults with lower SES. However, differences in cancer mortality were substantially larger by education than by race, indicating that SES plays a major role in driving racial disparities in cancer mortality. Overall cancer mortality rates were higher in Black adults than in White adults with the same education level by 7%–28% among males and by 2%–43% among females. Within each race, however, overall cancer mortality rates were higher in adults with ≤12 years of education than in those with ≥16 years of education by 143%–192% among males and by 71%–140% among females. Mortality from all cancers combined was 21% higher in nonmetropolitan than in large metropolitan counties, with the greatest differences for lung (45%) and cervical (36%) cancers and the smallest for prostate, female breast, and pancreatic cancers (7%–8%). By congressional district, the highest cancer mortality rates both overall and for lung, colorectal, and breast cancers were largely found in the South and East North‐Central division of the Midwest; however, for prostate cancer, there was no distinct geographic pattern. Sociodemographic groups that had higher cancer mortality generally had higher exposure to risk factors, lower health insurance coverage, and limited access to cancer prevention, early detection, and treatment compared with groups that had lower cancer mortality, largely reflecting fundamental disparities in SDOH. Mitigating cancer disparities in the United States requires intersectoral stakeholder engagement, targeted funding, effective policies at the federal, state, and local levels, and broad implementation of evidence‐based interventions, such as expanding health insurance coverage, including through strengthening Marketplaces and protecting and expanding access to Medicaid.

    2026CA a cancer journal for clinicians(2026)引用:14
    引用
    AI阅读
    加入学术空间
    5Methods of a Multi-State Rapid-Response Survey Designed to Close Evidence Gaps in Tobacco Use and Related Disparities in the U.S.
    Minal Patel, Presley Cannon, Laurel Gibson, Tyler Nighbor, Aya Carus, Shanshan Wang, Michele Salomon,Nigar Nargis

    INTRODUCTION:Tobacco use remains a significant public health challenge in the U.S., particularly in high-tobacco-burden states in the Midwest and South (Alabama, Arkansas, Indiana, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Ohio, Oklahoma, South Carolina, Tennessee, and West Virginia). Despite higher smoking prevalence and tobacco-related health disparities, little up-to-date information on correlates of tobacco use and emerging issues specific to this region is available for advocates and policymakers. Therefore, an online rapid-response survey was developed to provide timely and cost-effective information. METHODS:A total of 12,300 adults (aged 18-65 years) were surveyed from April to May 2023 and 2024 on tobacco use behaviors, harm perceptions, attitudes toward tobacco control policies, and access and use of cessation resources in high- versus 4 low-tobacco-burden states (California, Illinois, Maryland, and Virginia). Data were weighted to each state's population, enabling comprehensive analysis of regional and subpopulation differences. RESULTS:Weighted pooled data from both waves in high-tobacco-burden states revealed the highest prevalence of current tobacco use in Arkansas (42.8%) and the lowest in Missouri (29.7%). Cigarette use was most common in West Virginia (25.8%) and least common in South Carolina (17.6%), notably higher than the 10.9%-14.3% rates in low-tobacco-burden states. The use of other tobacco products, including E-cigarettes (16.6%) and oral nicotine pouches (3.5%), was also relatively high in high-tobacco-burden states. CONCLUSIONS:This rapid-response survey provides timely data to inform tobacco control policies in high-tobacco-burden states. Tobacco use and related data can aid in developing more effective interventions and clinical guidelines.

    2026American journal of preventive medicine(2026)引用:8
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2054 篇论文

    合作机构(100)

    国家癌症研究所合作论文 170
    美国国家卫生研究院合作论文 137
    埃默里大学合作论文 132
    弗雷德·哈钦森癌症研究中心合作论文 130
    哈佛大学合作论文 119
    温纳贝戈医学中心合作论文 113
    华盛顿大学合作论文 98
    卡罗琳斯卡医学院合作论文 98
    犹他大学合作论文 90
    墨尔本大学合作论文 89

    机构统计